welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- login
First Patient Dosed in Phase II Clinical Trial in Duchenne Muscular Dystrophy
Antisense Therapeutics today announced dosing of the first patient in a Phase II clinical trial of its immunomodulatory therapy, ATL1102, in patients with Duchenne Muscular Dystrophy (DMD).
Commencement of the trial represents an important development milestone for the Company and for patients seeking better and safer treatments.
ATL1102 is an inhibitor of CD49d expression on certain immune cells (T cells). DMD patients who have a greater number of T cells with high levels of CD49d on their surface have more severe and rapid disease progression.
rareRelated
-
Hope in Translation: Bringing Gene Therapy to the ClinicIn 1987, scientists first uncovered the ...
-
Aerobic Exercise in Boys With Duchenne Muscular Dystrophy (DMD)This research study wants to learn more ...
-
Catabasis Pharmaceuticals Initiates Phase 3 PolarisDMD Clinical Trial For Edasalonexent In Duchenne Muscular Dystrop...Catabasis Pharmaceuticals, Inc., a clini...
-
Stacking Exercises Aid the Decline in FVC and Sick TimeDuchenne Muscular Dystrophy is complicat...
-
Annemieke Aartsma-Rus, PhDDr. Annemieke Aartsma-Rus played an impo...
-
Therapeutic advances in muscular dystrophyThe muscular dystrophies comprise a hete...
-
Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double...Background: Duchenne muscular dystrophy...